SLRN Stock Overview
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Acelyrin, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.35 |
| 52 Week High | US$29.88 |
| 52 Week Low | US$4.14 |
| Beta | 0 |
| 1 Month Change | -34.39% |
| 3 Month Change | -45.90% |
| 1 Year Change | -81.49% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -81.49% |
Recent News & Updates
Shareholder Returns
| SLRN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 2.6% | 4.7% | 0.7% |
| 1Y | -81.5% | 2.7% | 23.9% |
Return vs Industry: SLRN underperformed the US Biotechs industry which returned 2.9% over the past year.
Return vs Market: SLRN underperformed the US Market which returned 24.2% over the past year.
Price Volatility
| SLRN volatility | |
|---|---|
| SLRN Average Weekly Movement | 9.6% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: SLRN's share price has been volatile over the past 3 months.
Volatility Over Time: SLRN's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 135 | Shao-Lee Lin | www.acelyrin.com |
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company’s lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease.
Acelyrin, Inc. Fundamentals Summary
| SLRN fundamental statistics | |
|---|---|
| Market cap | US$420.38m |
| Earnings (TTM) | -US$381.64m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.1x
P/E RatioIs SLRN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SLRN income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$381.64m |
| Earnings | -US$381.64m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 13, 2024
| Earnings per share (EPS) | -3.86 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did SLRN perform over the long term?
See historical performance and comparison